Alzamend Neuro, Inc. (ALZN) Stock Price & Analysis
Alzamend Neuro, Inc. (ALZN) closed at USD 1.28 on Thursday, October 15, 2026, down 5.19% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 1.35; the Oct 15, 2026 session ranged USD 1.28–1.33 on volume of 14,799 shares. Market capitalization is $6.18M, with a 52-week range of USD 0.84–2.68 (NCM). Source: Nexqual, retrieved October 16, 2026 at 05:11 UTC.
Also available as compact Markdown for AI agents: nexqual.com/ALZN.md
Key facts (ALZN)
- Analysts: Buy (mean 2.00 on a 1–5 scale) (1 analysts), mean target USD 26 (range 26–26).
- Total return with dividends: 1Y -45.8% vs S&P 500 +18.1%; 5Y -100.0% vs S&P 500 +85.1%.
Analysts (ALZN)
Consensus Buy (mean 2.00 on a 1–5 scale), 1 analysts; mean target USD 26 (low 26, high 26).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-08-19 | Ascendiant Capital | Target raised | Buy | $25 → $26 |
Total return (dividends reinvested) (ALZN)
| 1Y (from 2025-10-16) | 5Y (from 2021-10-11) | |
|---|---|---|
| Total return | -45.8% | -100.0% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | -45.9% | -79.0% |
| Volatility (annualized) | 83.3% | 90.8% |
| Max drawdown | -67.1% (Oct 2025→Apr 2026) | -100.0% (Nov 2021→Apr 2026) |
Key Statistics (as of October 16, 2026 at 05:11 UTC)
| Price | USD 1.28 |
|---|---|
| Change | ▼ 5.19% (down) |
| Previous Close | USD 1.35 |
| Open | USD 1.32 |
| Day Range | USD 1.28 – 1.33 |
| 52-Week Range | USD 0.84 – 2.68 |
| Volume | 14,799 shares |
| Market Cap | $6.18M |
| Exchange | NCM |
Technical Analysis (ALZN)
Nexqual's technical model rates ALZN "SELL" based on 1 bullish and 5 bearish signals across 127 daily candles, as of October 16, 2026 at 05:11 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 31.43 (neutral) |
| vs SMA50 | Below (USD 1.6) |
| MACD | -0.1 (negative) |
Analyst Ratings (ALZN)
Wall Street analysts rate ALZN "Buy" based on 1 analysts, with a mean price target of USD 26 (range USD 26–26), per Nexqual as of October 16, 2026 at 05:11 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 1 |
| Mean Target | USD 26 |
| High Target | USD 26 |
| Low Target | USD 26 |
| Buy / Hold / Sell | 1 / 0 / 0 |
Earnings (ALZN)
| EPS Estimate | USD -0.23 |
|---|---|
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-07-31 | USD -0.68 vs est -0.56 ▼ miss |
| 2026-04-30 | USD -0.74 vs est -0.67 ▼ miss |
| 2026-01-31 | USD -0.58 vs est -0.53 ▼ miss |
| 2025-10-31 | USD -0.3 vs est -1.96 ▲ beat |
Source: Nexqual, October 16, 2026 at 05:11 UTC.
Financials & Fundamentals (ALZN)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -163.23% |
| Current Ratio | 3.01 |
| Total Cash | $7.59M |
| Total Debt | $0 |
Source: Nexqual, October 16, 2026 at 05:11 UTC.
Financial Health Score (ALZN)
Nexqual rates Alzamend Neuro, Inc.'s overall financial health "Weak" across five dimensions, as of October 16, 2026 at 05:11 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Mixed — $8M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$7M (TTM) |
| Efficiency | Critical — ROE -163%, ROA -76.4% |
Ownership (ALZN)
| Insider Ownership | +2.66% |
|---|---|
| Institutional Ownership | +56.35% |
| Shares Outstanding | 4.83M |
| Float | 4.81M |
| Short % of Float | +2.37% |
Source: Nexqual, October 16, 2026 at 05:11 UTC.
Leadership (ALZN)
Alzamend Neuro, Inc. is led by Stephan Jackman (age 49), CEO & Director, per Nexqual as of October 16, 2026 at 05:11 UTC.
| CEO & Director | Stephan Jackman (age 49) |
|---|---|
| Founder & Vice Chairman | Milton Charles Ault (age 55) |
| Chief Financial Officer | David J. Katzoff (age 63) |
| Executive VP, General Counsel & Director | Henry C. W. Nisser (age 56) |
| Senior Vice President of Finance | Kenneth S. Cragun (age 64) |
Major Backers & Investors (ALZN)
Notable institutional backers of Alzamend Neuro, Inc. include Kmt Wealth Management, LLC , Kingsbury Capital Investment Advisors LLC, Fidelity, according to Nexqual as of October 16, 2026 at 05:11 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Kmt Wealth Management, LLC | 27.54% |
| Kingsbury Capital Investment Advisors LLC | 27.54% |
| Fidelity | 0.51% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 0.76% |
| Geode Capital | 0.55% |
Source: Nexqual, October 16, 2026 at 05:11 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| RYTM | Rhythm Pharmaceuticals, Inc. | USD 87.97 | ▲ 1.57% |
| BLTE | Belite Bio, Inc | USD 152.62 | ▲ 0.49% |
| IOVA | Iovance Biotherapeutics, Inc. | USD 14.72 | ▲ 1.52% |
| PRAX | Praxis Precision Medicines, Inc | USD 248.24 | ▲ 2.01% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 44.12 | ▲ 4.11% |
| SYRE | Spyre Therapeutics, Inc. | USD 80.1 | ▼ 0.44% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 16, 2026 at 05:11 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt